Evofem Biosciences Inc represents a strong commitment to women's healthcare and empowerment. With a focus on providing innovative solutions to meet unmet needs, Evofem Biosciences Inc strives to improve the lives of women worldwide. Grounded in their corporate philosophy of putting women first, the company is dedicated to supporting female reproductive health through the development of safe and effective products. Evofem Biosciences Inc is driven by a belief in the transformative power of science and technology, aiming to enhance women's quality of life and empower them to take charge of their own well-being.

Evofem Biosciences Inc primarily operates in the United States.

Evofem Biosciences Inc has achieved several significant milestones since its inception. Some notable achievements include the successful completion of Phase 3 clinical trials for its flagship product, Amphora, a non-hormonal contraceptive gel. The company also received FDA approval for Amphora in 2020, marking a major breakthrough in the field of women's healthcare. In addition, Evofem Biosciences Inc has secured strategic partnerships, expanded its global reach, and made substantial progress in research and development efforts, solidifying its position as a leader in innovative contraception solutions. These achievements demonstrate the company's commitment to revolutionizing women's reproductive health.

Evofem Biosciences Inc is a pharmaceutical company dedicated to developing innovative women's health products. Founded in 2009, the company focuses on providing novel contraceptive and sexual health solutions. Evofem's flagship product is Phexxi™, the first non-hormonal, on-demand contraceptive gel approved by the FDA. The company's mission is to empower women by offering them effective and convenient contraceptive options. Evofem Biosciences Inc is committed to advancing the field of women's health and addressing the unmet needs of women worldwide. With its emphasis on research and development, Evofem Bio is poised to make a significant impact in the field of women's reproductive health.

Evofem Biosciences Inc faces competition from various companies in the market. Some of its main competitors include pharmaceutical and biotechnology companies such as Merck & Co., Inc., Johnson & Johnson, and Allergan plc. These competitors also specialize in developing and commercializing innovative healthcare products and may offer competing solutions in the same or similar therapeutic areas as Evofem Biosciences Inc. Evofem Biosciences Inc distinguishes itself through its focus on the development and promotion of female reproductive health products.

Evofem Biosciences Inc is primarily active in the pharmaceutical and biotechnology industries. As a leading company, Evofem Biosciences focuses on developing innovative medical solutions and pharmaceutical products for women's health. With a strong emphasis on empowering women and advancing their sexual and reproductive well-being, Evofem Biosciences aims to address unmet needs in contraception and various gynecological conditions. Through its cutting-edge research, Evofem Biosciences strives to revolutionize healthcare and make a positive impact on women's lives.

Evofem Biosciences Inc is a pharmaceutical company specializing in women's sexual and reproductive health. Their business model revolves around developing and commercializing innovative products to address unmet needs in contraception and prevention of sexually transmitted infections. Evofem Biosciences focuses on leveraging their proprietary Multipurpose Vaginal pH regulator (MVP-R) technology platform to develop non-hormonal contraceptive options and other novel products for women's health. With a commitment to advancing scientific research and empowering women's reproductive choices, Evofem Biosciences aims to deliver safe, effective, and convenient solutions that positively impact women's lives globally.

Evofem Biosciences KGV ir -0,55.

Evofem Biosciences KUV ir 0,07.

AlleAktien kvalitātes vērtējums Evofem Biosciences ir 5/10.

gaidāmā Evofem Biosciences apgrozījums ir 127,34 milj. USD.

gaidāmā Evofem Biosciences peļņa ir -16,37 milj. USD.

Evofem Biosciences Inc is a company specialized in developing products that meet the needs of women in terms of sexual health and contraception. The company is headquartered in San Diego and conducts research and development, as well as marketing and distribution activities in the USA. The business model of Evofem Biosciences is based on developing and marketing products that improve women's health, promote their independence, and enhance their quality of life. The company operates in various sectors, including the "contraception" sector and the "sexual health" sector. In the "contraception" sector, the company has developed the product "Phexxi". Phexxi is a non-hormonal gel that protects women from unintended pregnancy. The gel is inserted into the vagina before intercourse and forms a barrier that prevents sperm from entering. Compared to other contraceptive methods, Phexxi offers the advantage of immediate effectiveness and only needs to be used when needed. In the "sexual health" sector, the company has developed the product "Giapreza". Giapreza is a medication that increases blood pressure in patients with severe hypotension. The medication is used in hospitals and emergency medicine and can help save patients' lives. In addition to these products, Evofem Biosciences also conducts research and development activities to develop further innovative products that improve women's health. The company invests in the research and development of new therapies for diseases that affect women, such as endometriosis, polycystic ovary syndrome, and osteoporosis. The business model of Evofem Biosciences is based on distributing its products through partners and distribution channels in healthcare. The company collaborates with partners to promote and distribute its products. Additionally, the company also has a direct sales strategy to sell its products directly to customers. Overall, the company has a promising business model as it specializes in the needs of women and develops innovative products that meet the needs of this target group. With its products and research activities, the company is well positioned to continue growing in the future and expand its market influence.

Evofem Biosciences izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Evofem Biosciences vai uzņēmums nedod dividendes.

Evofem Biosciences ISIN ir US30048L1044.

Evofem Biosciences WKN ir A2JBZC.

Evofem Biosciences simbols ir EVFM.

Pēdējo 12 mēnešu laikā Evofem Biosciences maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Evofem Biosciences plāno maksāt dividendes 0 USD apmērā.

Evofem Biosciences pašreizējā dividendu rentabilitāte ir .

Evofem Biosciences maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Evofem Biosciences pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Evofem Biosciences tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Evofem Biosciences apmērā 0 USD, kas tika izmaksāta 17.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 17.09.2024..

Pēdējās dividendes izmaksa notika 17.09.2024..

Gadā 2023, Evofem Biosciences izmaksāja 0 USD dividendes.

Evofem Biosciences dividendes tiek izmaksātas USD.